Restricted accessReview articleFirst published online 2023-10
Effectiveness and safety of opioids on breathlessness and exercise endurance in patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis of randomised controlled trials
Opioids are recommended to treat advanced refractory dyspnoea despite optimal therapy by the American Thoracic Society clinical practice guidelines, while newly published randomised controlled trials of opioids in chronic obstructive pulmonary disease yield conflicting results.
Aim:
This study aimed to evaluate the effectiveness and safety of opioids for patients with chronic obstructive pulmonary disease.
Design:
Systematic review and meta-analysis (PROSPERO CRD42021272556).
Data sources:
Databases of PubMed, EMBASE and CENTRAL were searched from inception to 2022 for eligible randomised controlled trials.
Results:
Twenty-four studies including 975 patients, were included. In cross-over studies, opioids improved breathlessness (standardised mean difference, −0.43; 95% CI, −0.55 to −0.30; I2 = 18%) and exercise endurance (standardised mean difference, 0.22; 95% CI, 0.02–0.41; I2 = 70%). However, opioids failed to improve dyspnoea (standardised mean difference, −0.02; 95% CI, −0.22 to 0.19; I2 = 39%) and exercise endurance (standardised mean difference, 0.00; 95% CI, −0.27 to 0.27; I2 = 0%) in parallel control studies that administered sustained-release opioids for more than 1 week. The opioids used in most crossover studies were short-acting and rarely associated with serious adverse effects. Only minor side effects such as dizziness, nausea, constipation and vomiting were identified for short-acting opioids.
Conclusions:
Sustained-release opioids did not improve dyspnoea and exercise endurance. Short-acting opioids appeared to be safe, have potential to lessen dyspnoea and improve exercise endurance, supporting benefit in managing episodes of breathlessness and providing prophylactic treatment for exertional dyspnoea.
AdeloyeDSongPZhuY, et al. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: A systematic review and modelling analysis. Lancet Respir Med2022; 10: 447–458.
2.
GBD-2015-Chronic-Respiratory-Disease-Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med2017; 5: 691–706.
3.
CaretteHZysmanMMorelot-PanziniC, et al. Prevalence and management of chronic breathlessness in COPD in a tertiary care center. BMC Pulm Med2019; 19: 95.
4.
O’DonnellDEMilneKMJamesMD, et al. Dyspnea in COPD: New mechanistic insights and management implications. Adv Ther2020; 37: 41–60.
5.
WaschkiBKirstenAHolzO, et al. Physical activity is the strongest predictor of all-cause mortality in patients with COPD: A prospective cohort study. Chest2011; 140: 331–342.
6.
MollMQiaoDReganEA, et al. Machine learning and prediction of all-cause mortality in COPD. Chest2020; 158: 952–964.
7.
VaesAWGarcia-AymerichJMarottJL, et al. Changes in physical activity and all-cause mortality in COPD. Eur Respir J2014; 44: 1199–1209.
8.
ParshallMBSchwartzsteinRMAdamsL, et al. An official American Thoracic Society statement: Update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med2012; 185: 435–452.
9.
AmbrosinoNFracchiaC. Strategies to relieve dyspnoea in patients with advanced chronic respiratory diseases: A narrative review. Pulmonology2019; 25: 289–298.
10.
HanMKMartinezCHAuDH, et al. Meeting the challenge of COPD care delivery in the USA: A multiprovider perspective. Lancet Respir Med2016; 4: 473–526.
11.
SmallwoodNCurrowDBoothS, et al. Differing approaches to managing the chronic breathlessness syndrome in advanced COPD: A multi-national survey of specialists. COPD2018; 15: 294–302.
12.
MaddocksMLovellNBoothS, et al. Palliative care and management of troublesome symptoms for people with chronic obstructive pulmonary disease. Lancet2017; 390: 988–1002.
13.
JohnsonMJCurrowDC. Opioids for breathlessness: A narrative review. BMJ Support Palliat Care2020; 10: 287–295.
MarciniukDDGoodridgeDHernandezP, et al. Managing dyspnea in patients with advanced chronic obstructive pulmonary disease: A Canadian Thoracic Society clinical practice guideline. Can Respir J2011; 18: 69–78.
16.
NiciLMammenMJCharbekE, et al. Pharmacologic management of chronic obstructive pulmonary disease: An official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med2020; 201: e56–e69.
17.
JenningsALDaviesANHigginsJP, et al. A systematic review of the use of opioids in the management of dyspnoea. Thorax2002; 57: 939–944.
18.
EkströmMNilssonFAbernethyAA, et al. Effects of opioids on breathlessness and exercise capacity in chronic obstructive pulmonary disease: A systematic review. Ann Am Thorac Soc2015; 12: 1079–1092.
19.
BarnesHMcDonaldJSmallwoodN, et al. Opioids for the palliation of refractory breathlessness in adults with advanced disease and terminal illness. Cochrane Database Syst Rev2016; 3: Cd011008.
20.
VozorisNT. Opioids for dyspnea in chronic obstructive pulmonary disease: Short on the details. Am J Respir Crit Care Med2021; 203: 266–267.
21.
AbdallahSJWilkinson-MaitlandCSaadN, et al. Effect of morphine on breathlessness and exercise endurance in advanced COPD: A randomised crossover trial. Eur Respir J2017; 50(4) 1701235.
22.
JanowiakPKrajnikMPodolecZ, et al. Dosimetrically administered nebulized morphine for breathlessness in very severe chronic obstructive pulmonary disease: A randomized, controlled trial. BMC Pulm Med2017; 17: 186.
23.
CurrowDLouwSMcCloudP, et al. Regular, sustained-release morphine for chronic breathlessness: A multicentre, double-blind, randomised, placebo-controlled trial. Thorax2020; 75: 50–56.
24.
FerreiraDHLouwSMcCloudP, et al. Controlled-release oxycodone vs. placebo in the treatment of chronic Breathlessness: A multisite randomized placebo controlled trial. J Pain Symptom Manag2020; 59: 581–589.
25.
AhmadiZBernelidECurrowDC, et al. Prescription of opioids for breathlessness in end-stage COPD: A national population-based study. Int J Chron Obstruct Pulmon Dis2016; 11: 2651–2657.
26.
CurrowDCJohnsonMJPollackA, et al. Breathlessness and opioid prescribing in COPD in general practice: A cross-sectional, observational study. ERJ Open Res2020; 6(2): 00299-2019.
27.
VozorisNT. Opioid utility for dyspnea in chronic obstructive pulmonary disease: A complicated and controversial story. Ann Palliat Med2020; 9: 571–578.
28.
VozorisNTWangXFischerHD, et al. Incident opioid drug use and adverse respiratory outcomes among older adults with COPD. Eur Respir J2016; 48: 683–693.
29.
BaillargeonJSinghGKuoYF, et al. Association of opioid and benzodiazepine use with adverse respiratory events in older adults with chronic obstructive pulmonary disease. Ann Am Thorac Soc2019; 16: 1245–1251.
30.
EkströmMPBornefalk-HermanssonAAbernethyAP, et al. Safety of benzodiazepines and opioids in very severe respiratory disease: National prospective study. BMJ2014; 348: g445.
31.
CurrowDCMcDonaldCOatenS, et al. Once-daily opioids for chronic dyspnea: A dose increment and pharmacovigilance study. J Pain Symptom Manag2011; 42: 388–399.
32.
SterneJACSavovićJPageMJ, et al. RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ2019; 366: l4898.
33.
The Grading of Recommendations Assessment, Dev-elopment and Evaluation (GRADE) Working Group. Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. 2013. https://gdt.gradepro.org/app/handbook/handbook.html
34.
WanXWangWLiuJ, et al. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol2014; 14: 135.
35.
ElbourneDRAltmanDGHigginsJP, et al. Meta-analyses involving cross-over trials: Methodological issues. Int J Epidemiol2002; 31: 140–149.
36.
HigginsJPTThomasJChandlerJet al (eds). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. https://training.cochrane.org/handbook
37.
JonesPWBeehKMChapmanKR, et al. Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med2014; 189: 250–255.
38.
AbernethyAPCurrowDCFrithP, et al. Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ2003; 327: 523–528.
39.
WoodcockAAGeddesDMJohnsonM. Breathlessness, alcohol, and opiates. New Engl J Med1982; 306: 1363–1364.
40.
BeaufordWSaylorTTStansburyDW, et al. Effects of nebulized morphine sulfate on the exercise tolerance of the ventilatory limited COPD patient. Chest1993; 104: 175–178.
41.
EiserNDenmanWTWestC, et al. Oral diamorphine: Lack of effect on dyspnoea and exercise tolerance in the “pink puffer” syndrome. Eur Respir J1991; 4: 926–931.
42.
JankelsonDHosseiniKMatherLE, et al. Lack of effect of high doses of inhaled morphine on exercise endurance in chronic obstructive pulmonary disease. Eur Respir J1997; 10: 2270–2274.
43.
JensenDAlsuhailAViolaR, et al. Inhaled fentanyl citrate improves exercise endurance during high-intensity constant work rate cycle exercise in chronic obstructive pulmonary disease. J Pain Symptom Manag2012; 43: 706–719.
44.
JohnsonMAWoodcockAAGeddesDM. Dihydrocodeine for breathlessness in “pink puffers”. Br Med J1983; 286: 675–677.
45.
LeungRHillPBurdonJ. Effect of inhaled morphine on the development of breathlessness during exercise in patients with chronic lung disease. Thorax1996; 51: 596–600.
46.
LightRWMuroJRSatoRI, et al. Effects of oral morphine on breathlessness and exercise tolerance in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis1989; 139: 126–133.
47.
LightRWStansburyDWWebsterJS. Effect of 30 mg of morphine alone or with promethazine or prochlorperazine on the exercise capacity of patients with COPD. Chest1996; 109: 975–981.
48.
MunckLKChristensenCBPedersenL, et al. Codeine in analgesic doses does not depress respiration in patients with severe chronic obstructive lung disease. Pharmacol Toxicol1990; 66: 335–340.
49.
NosedaACarpiauxJPMarksteinC, et al. Disabling dyspnoea in patients with advanced disease: Lack of effect of nebulized morphine. Eur Respir J1997; 10: 1079–1083.
50.
PoolePJVealeAGBlackPN. The effect of sustained-release morphine on breathlessness and quality of life in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med1998; 157: 1877–1880.
51.
VerberktCAvan den Beuken-van EverdingenMHJScholsJMGA, et al. Effect of sustained-release morphine for refractory breathlessness in chronic obstructive pulmonary disease on health status: A randomized clinical trial. JAMA Intern Med2020; 180: 1306–1314.
52.
WoodcockAAGrossERGellertA, et al. Effects of dihydrocodeine, alcohol, and caffeine on breathlessness and exercise tolerance in patients with chronic obstructive lung disease and normal blood gases. New Engl J Med1981; 305: 1611–1616.
53.
YoungIHDaviskasEKeenaVA. Effect of low dose nebulised morphine on exercise endurance in patients with chronic lung disease. Thorax1989; 44: 387–390.
54.
EkströmMFerreiraDChangS, et al. Effect of regular, low-dose, extended-release morphine on chronic breathlessness in chronic obstructive pulmonary disease: the BEAMS randomized clinical trial. JAMA2022; 328: 2022–2032.
55.
MasoodARReedJWThomasSH. Lack of effect of inhaled morphine on exercise-induced breathlessness in chronic obstructive pulmonary disease. Thorax1995; 50: 629–634.
56.
SimonSTBauseweinCSchildmannE, et al. Episodic breathlessness in patients with advanced disease: A systematic review. J Pain Symptom Manag2013; 45: 561–578.
57.
JohnsonMJHuiDCurrowDC. Opioids, exertion, and dyspnea: A review of the evidence. Am J Hosp Palliat Care2016; 33: 194–200.
58.
ShohratiMGhaneiMHarandiAA, et al. Effect of nebulized morphine on dyspnea of mustard gas-exposed patients: A double-blind randomized clinical trial study. Pulm Med2012; 2012: 610921.
59.
BauseweinCSimonST. Shortness of breath and cough in patients in palliative care. Dtsch Arztebl Int2013; 110: 563–571. quiz 572.
60.
SpruitMAPittaFMcAuleyE, et al. Pulmonary rehabilitation and physical activity in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med2015; 192: 924–933.
61.
VerberktCAvan den Beuken-van EverdingenMHJScholsJMGA, et al. Respiratory adverse effects of opioids for breathlessness: A systematic review and meta-analysis. Eur Respir J2017; 50(5) 1701153.
62.
BanzettRBAdamsLO’DonnellCR, et al. Using laboratory models to test treatment: Morphine reduces dyspnea and hypercapnic ventilatory response. Am J Respir Crit Care Med2011; 184: 920–927.
63.
JohnsonMJBlandJMOxberrySG, et al. Opioids for chronic refractory breathlessness: Patient predictors of beneficial response. Eur Respir J2013; 42: 758–766.
64.
CurrowDCQuinnSEkstromM, et al. Can variability in the effect of opioids on refractory breathlessness be explained by genetic factors?BMJ Open2015; 5: e006818.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
